Reversible monoamine oxidase-A inhibitors in panic disorder.

Abstract

Monoamine oxidase (MAO) inhibitors are known to be effective in panic disorder, but a high incidence of adverse reactions have limited their use. The new, selective, and reversible MAO-A inhibitors exemplified by brofaromine and moclobemide do not require dietary restrictions, have fewer drug interactions, and are better tolerated. This paper reports a randomized, double-blind, 8-week trial in which the efficacy and safety of brofaromine was compared to clomipramine in patients with panic disorder with or without agoraphobia. Both treatments achieved a significant and comparable reduction in the number of panic attacks, and were equally effective in all the parameters measured. Side effects were typical of the drug class. Further trials are required to evaluate this promising new treatment.

• Authors: D Bakish, B M Saxena, R Bowen, J D'Souza
• Journal: Clinical neuropharmacology (Clin Neuropharmacol) Vol. 16 Suppl 2 Pg. S77-82 ( 1993) ISSN: 0362-5664 [Print] United States
• PMID: 8313401 (Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial)

Chemical References

• Monoamine Oxidase Inhibitors
• Piperidines
• brofaromine
• Monoamine Oxidase
• Clomipramine

Topics

• Agoraphobia (drug therapy, psychology)
• Clomipramine (adverse effects, therapeutic use)
• Double-Blind Method
• Humans
• Monoamine Oxidase (metabolism)
• Monoamine Oxidase Inhibitors (adverse effects, therapeutic use)
• Panic Disorder (drug therapy, psychology)
• Piperidines (adverse effects, therapeutic use)
• Psychiatric Status Rating Scales